Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.49 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | LMNA | P02545 | 7/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL2064209 | 0.88 | ALDH1A1 (0.79) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL2064212 | 0.88 | ALDH1A1 (0.79) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL2064712 | 0.86 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL2064710 | 0.86 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL31272367 | 0.85 | ALDH1A1 (0.83) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL27380337 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL10905907 | 0.85 | ALDH1A1 (0.60) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL3289690 | 0.84 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL6313398 | 0.84 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNATSHRMAPT | |
| Citric Acid SCHEMBL28138648 | 0.84 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0551434-A1 | HIGH AFFINITY TAMOXIFEN DERIVATIVES AND USES THEREOF. | UNIV TEXAS (US) | 1993-07-21 | — | — | EP | claimed |
| WO-1992006068-A1 | HIGH AFFINITY TAMOXIFEN DERIVATIVES AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-04-16 | — | — | WO | claimed |
| US-20250276953-A1 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-09-04 | — | — | US | disclosed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CATALENT PHARMA SOLUTIONS, LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240124419-A1 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-04-18 | — | — | US | disclosed |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS, LLC | 2024-03-14 | — | — | US | disclosed |
| US-20240050415-A1 | DACLATASVIR FOR USE IN TREATING LUNG AND PROSTATE CANCER | HENRY FORD HEALTH SYSTEM (US) | 2024-02-15 | — | — | US | disclosed |
| US-11879009-B2 | Multifunctional protein molecules comprising decorin and use thereof | CATALENT PHARMA SOLUTIONS, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230364084-A1 | METHODS FOR PREVENTING OR TREATING CONDITIONS RELATED TO PIKFYVE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-16 | — | — | US | disclosed |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | MEKANISTIC THERAPEUTICS LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-20100080789-A1 | THERAPEUTIC RIBONUCLEASES | QUINTESSENCE BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090175869-A1 | Pulsatile Dosing of Gossypol for Treatment of Disease | ASCENTA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090010878-A1 | Pulsatile dosing of gossypol for treatment of disease | ASCENTA THERAPEUTICS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080253997-A1 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS FROM TOXIC EXPOSURES | PERSCITUS BIOSCIENCES, LLC (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080095755-A1 | Methods and compositions for the treatment of cancer | QUINTESSENCE BIOSCIENCES, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080021095-A1 | Small Molecule Antagonists of Xiap Family Proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2008-01-24 | — | — | US | disclosed |
| US-20050261232-A1 | Non-natural ribonuclease conjugates as cytotoxic agents | QUINTESSENCE BIOSCIENCES, INC. (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CD2BP2, DSTN, SDCBP | MEN1 1307/4885ESR1 4665/4885ESR2 3866/4885 |
| US-20240124419-A1 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | HSPA5, HSPA2, PSMG3 | MEN1 4673/4885ESR1 1988/4885ESR2 968/4885 |
| US-11879009-B2 | Multifunctional protein molecules comprising decorin and use thereof | CD2BP2, DSTN, SDCBP | MEN1 1307/4885ESR1 4665/4885ESR2 3866/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | MEN1 1831/4885ESR1 276/4885ESR2 273/4885 |
| US-11673876-B2 | Substituted aminobenzyl heteroaryl compounds as EGFR and/or PI3K inhibitors | EGFR, ERBB2, ERBB3 | MEN1 1831/4885ESR1 276/4885ESR2 273/4885 |
| US-20090010878-A1 | Pulsatile dosing of gossypol for treatment of disease | BCL2, BAX, PHLPP2 | MEN1 702/4885ESR1 2706/4885ESR2 839/4885 |
| US-20090175869-A1 | Pulsatile Dosing of Gossypol for Treatment of Disease | BCL2, BAX, BAD | MEN1 685/4885ESR1 2421/4885ESR2 750/4885 |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | MEN1 1831/4885ESR1 276/4885ESR2 273/4885 |
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | BID, BAD, BIRC2 | MEN1 1010/4885ESR1 3781/4885ESR2 3121/4885 |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | BID, BAD, BIRC2 | MEN1 1010/4885ESR1 3781/4885ESR2 3121/4885 |
| US-20080021095-A1 | Small Molecule Antagonists of Xiap Family Proteins | XIAP, BIRC5, BIRC3 | MEN1 1626/4885ESR1 1396/4885ESR2 992/4885 |
| US-20230364084-A1 | METHODS FOR PREVENTING OR TREATING CONDITIONS RELATED TO PIKFYVE ACTIVITY | PIKFYVE, PPME1, MTMR1 | MEN1 2265/4885ESR1 4751/4885ESR2 3911/4885 |
| US-20080253997-A1 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS FROM TOXIC EXPOSURES | PRDX5, GPX1, GPX4 | MEN1 2821/4885ESR1 2198/4885ESR2 1375/4885 |
| US-20250276953-A1 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | SIRT6, SIRT2, SIRT1 | MEN1 929/4885ESR1 2167/4885ESR2 688/4885 |
| US-20050261232-A1 | Non-natural ribonuclease conjugates as cytotoxic agents | RNASE1, RNASEL, RNASEH1 | MEN1 3127/4885ESR1 3841/4885ESR2 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.